Table 1 Targeted next-generation sequencing of both tumors showing the same results with an identical activating mutation in the PIK3CA gene exon 20

BRAF

15

582–612

Wildtype

DDR2

3–18

1–342, 351–395, 432–586, 620–856

Wildtype

ERBB2

8, 19–21

302–321, 761–881

Wildtype

HRAS

2–4

1–35, 41–82, 105–150

Wildtype

KEAP1

2–6

1–34, 37–122, 127–437, 443–625

Wildtype

KRAS

2–4

4–66, 111–150

Wildtype

NFE2L2

2

16–104

Wildtype

NRAS

2–4

1–32, 45–83, 110–150

Wildtype

PIK3CA

1, 4, 7, 9, 20

66–117, 312–350, 418–435, 521–554, 980–1069

EX20: c.3140A>G p.H1047R

activating

PTEN

1–9

1–34, 39–267, 275–333, 343–366

Wildtype

RHOA

2, 3

3–89

Wildtype

TP53

5–9

133–260, 263–331

Wildtype